The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2013Mu Opioid Receptor Target for Levodopa-Induced Dyskinesia: Stop or Continue? (MOR4LID)
Objective/Rationale:
The mu opioid receptor (MOR) has long been proposed as an appealing target for managing levodopa-induced dyskinesia and therefore received attention from industry, which developed... -
Target Validation, 2013PARK14: Validation of a New Pre-clinical Model of Age-dependent PD
Objective/Rationale:
The gene PARK 14 (PLA2g6) is expressed in human brain, and numerous mutations in this gene were found to be associated with PD, but the mechanism of such association is... -
Research Grant, 2013Native Alpha-Synuclein Oligomers in Living Cells: Relevance for Diagnosing and Treating Parkinson’s Disease
Objective/Rationale:
Aggregation of the protein called alpha-synuclein in nerve cells produces the hallmark pathology (Lewy bodies) of Parkinson´s disease (PD). The pathological events... -
Target Validation, 2013Validation of a Novel Pre-Clinical Model of Dyskinesia in PD
Promising Outcomes of Original Grant:
Our original target validation grant was aimed at deciphering the role of the protein beta-arrestin2 in the manifestation of beneficial versus dyskinetic side... -
Rapid Response Innovation Awards, 2013Topography of Vulnerability to Alpha-synuclein Fibrils in the Cerebral Cortex
Objective/Rationale:
In Parkinson’s disease, the neocortex (outer layer of the brain’s cerebral hemispheres, made of six layers) is less vulnerable than the allocortex (fewer than six... -
Rapid Response Innovation Awards, 2013Genetic Validation of a New Causative Gene for Familial and Sporadic Parkinson’s Disease
Objective/Rationale:
Genetic and environmental factors both have been linked to Parkinson’s disease (PD). Over the last 15 years, many PD susceptibility genes have been described. However...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.